Navigation Links
PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022
Date:12/10/2013

London (PRWEB) December 10, 2013

PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard once- or twice-daily therapies.

A dip in sales caused by Actos patent expiry in 2012 and three insulin products’ patent expiry by 2015 will be offset by 16 pipeline product launches over the forecast period. Byetta’s patent expiration in 2016 will not have a major impact on the market as its sales have been constantly declining, with Victoza and Bydureon overtaking its shares.

Scope

-Overview of type 2 diabetes including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pioneer in Therapeutic Patient Education, Professor Jean-Philippe Assal, Wins 2013 IDF Europe Prize in Diabetes for Long-Standing Achievement
2. Researcher studying biological factors of blood glucose variability wins 2013 IDF Europe Prize in Diabetes for Young Researcher
3. Best Practices in Patient Recruitment and Retention for Diabetes Trials, New Life Science Webinar Hosted by Xtalks
4. Enteroviruses Cause Type 1 Diabetes; New Studies Support Dr. Hanan Polansky’s Microcompetition Theory
5. Cardiometabolic Health Congress Faculty Deliver Expert Guidance on Novel Management Strategies for Diabetes and its Comorbidities
6. Investigational Diabetes Drug May Also Have Future As Treatment for Parkinsons Disease
7. Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
8. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
9. Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
10. Lillys Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes
11. Results of new exploratory analyses assessing the incidence of hypoglycemia with linagliptin in adults with type 2 diabetes announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 Deerfield Management Company, L.P. today ... L.P., which will invest in groundbreaking advancements in science ... cancer, and orphan diseases. The venture capital fund will ... are developed and improve the way healthcare is delivered ... largest healthcare-focused venture funds in the sector, will donate ...
(Date:7/28/2015)... 2015 BioStructures, LLC, a privately held ... milestone of 4,000 implantations of Signafuse® Bioactive Bone ... early 2014 as a bone void filler indicated ... This is a distinguished status among recently cleared ... new synthetic products have received clearance with a ...
(Date:7/28/2015)... ZIONA, Israel , ... Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing ... products, today announced that Shomrat Shurtz has been ... 20, 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... over 25 years of experience in marketing, regulatory ...
(Date:7/27/2015)... , July 27, 2015 /PRNewswire/ - Quest PharmaTech ... company developing and commercializing products for the treatment of ... Quest announces that it has closed a $1,000,000 unit ... placement of 16,666,667 units of the Company at a ... of one common share and one common share purchase ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Revolutionary Bone Graft Exceeds Expectations 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Quest PharmaTech Closes $1,000,000 Private Placement 2
... ALISO VIEJO, Calif., May 5 ... Genomic Hybridization (CGH) using oligonucleotide arrays through a partnership ... abnormalities that are associated with over 270 genetic syndromes ... whole genome and mitochondrial array. The partnership with ...
... NEEDHAM, Mass., May 5 A new ... to improve both building systems performance and energy ... with much of the savings linked to low-cost modifications. ... Engineering, Inc. (EH&E), a leading Massachusetts-based environmental and ...
... HUBBARD, Ohio, May 5 NanoLogix, Inc. (Pink Sheets: ... technology at booth 749 during the 109th Annual ASM ... in Philadelphia May 17th - 21st. The ASM meeting ... NanoLogix will be Dr. Sergey Gazenko and CEO Bret ...
Cached Biology Technology:Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College of Medicine 2New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More 2NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents 2NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents 3
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... A major challenge for cancer biologists is figuring out which ... cell are most important for driving the cancer,s spread. ... have now pinpointed a gene that appears to drive progression ... cancer accounting for about 15 percent of lung cancer cases. ...
... Richmond and Providence cities scattered across the eastern ... common, all have coal-fired power plants. A new study ... Indianapolis is among the first to investigate mercury deposits ... The study, which appears in the July 2011 ...
... & Melinda Gates Foundation has awarded Delft University of Technology ... Aim of this project is to develop new technology for ... lines, and at costs affordable to the poor in developing ... this grant today at the AfricaSan conference in Rwanda (www.africasan3.com) ...
Cached Biology News:New lung-cancer gene found 2Soil samples reveal urban mercury footprints 2Reinventing the toilet for safe and affordable sanitation 2
Component in MasterPure™ Purification Kits...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
...
... Signets FAST RED Chromogen ... chromogen,tablets and substrate buffer. FAST ... of alkaline phosphatase to produce ... noise. The ...
Biology Products: